Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.45 |
| ▸ | TUBB | P07437 | 5/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368835 | 1.00 | CYP3A4 (0.67) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL17547637 | 0.93 | CYP3A4 (0.58) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL16246508 | 0.93 | CYP3A4 (0.67) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL17547639 | 0.92 | CYP3A4 (0.66) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL20329876 | 0.90 | CYP3A4 (0.65) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL16264011 | 0.89 | CYP3A4 (0.67) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL3355849 | 0.88 | CYP3A4 (0.66) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL16246493 | 0.87 | CYP3A4 (0.67) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL16264012 | 0.86 | CYP3A4 (0.60) | CYP3A4MAPTHPGDMEN1KMT2A | |
| SCHEMBL17547638 | 0.86 | CYP3A4 (0.50) | CYP3A4MAPTHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023101252-A1 | OPHTHALMIC NANOEMULSION COMPOSITION FOR TREATING MACULAR DEGENERATION AND METHOD FOR PREPARING SAME | 인제대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2017091473-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707445-B2 | Composition for blocking angiogenesis | FLT4, KDR, VEGFA | CYP3A4 4634/4885MAPT 2741/4885HPGD 573/4885 |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885 |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | FLT4, KDR, VEGFA | CYP3A4 4634/4885MAPT 2741/4885HPGD 573/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.